The ROE as of September 2024 (TTM) for Arcus Biosciences, Inc. (RCUS) is -42.86%

According to Arcus Biosciences, Inc.’s latest financial reports and current stock price. The company's current ROE is -42.86%. This represents a change of 269.48% compared to the average of -11.60% of the last 4 quarters.

Arcus Biosciences, Inc. (RCUS) Historical ROE (quarterly & annually)

How has RCUS ROE performed in the past?

The mean historical ROE of Arcus Biosciences, Inc. over the last ten years is -30.50%. The current -42.86% ROE has changed 40.49% with respect to the historical average. Over the past ten years (40 quarters), RCUS's ROE was at its highest in in the December 2021 quarter at 33.20%. The ROE was at its lowest in in the March 2020 quarter at -19.73%.

Arcus Biosciences, Inc. (RCUS) ROE by Quarter and Year

Discovering the peaks and valleys of Arcus Biosciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Arcus Biosciences, Inc. (RCUS) Average ROE

How has RCUS ROE performed in the past?

The current ROE of Arcus Biosciences, Inc. (RCUS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Arcus Biosciences, Inc. (RCUS) ROE vs. Peers

How is RCUS’s ROE compared to its peers?

Arcus Biosciences, Inc.’s ROE is greater than Cullinan Oncology, Inc. (-28.37%), greater than Annexon, Inc. (-44.68%), greater than Structure Therapeutics Inc. (-20.15%), greater than Relay Therapeutics, Inc. (-43.66%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Inozyme Pharma, Inc. (-68.93%), greater than VectivBio Holding AG (-56.92%), less than PTC Therapeutics, Inc. (57.03%), greater than Blueprint Medicines Corporation (-85.25%), less than Krystal Biotech, Inc. (13.36%), greater than Intercept Pharmaceuticals, Inc. (-78.24%), greater than Madrigal Pharmaceuticals, Inc. (-95.61%), greater than Immix Biopharma, Inc. (-86.48%), less than CNS Pharmaceuticals, Inc. (428.91%), greater than Hepion Pharmaceuticals, Inc. (-328.66%), greater than Freeline Therapeutics Holdings plc (-110.68%), less than AVROBIO, Inc. (29.68%), greater than Icosavax, Inc. (-41.24%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), greater than iTeos Therapeutics, Inc. (-18.19%), greater than TScan Therapeutics, Inc. (-59.83%),

Build a custom stock screener for Arcus Biosciences, Inc. (RCUS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcus Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Arcus Biosciences, Inc. (RCUS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Arcus Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.